OncoMatch/Clinical Trials/NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Is NCT05490472 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-2485 (Aurora A inhibitor) and JAB-2485 (Aurora A inhibitor) for solid tumors.
Treatment: JAB-2485 (Aurora A inhibitor) · JAB-2485 (Aurora A inhibitor) — This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Triple-Negative Breast Cancer
Small Cell Lung Cancer
Biomarker criteria
Allowed: ARID1A mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: existing therapy known to provide clinical benefit
Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition
Lab requirements
Blood counts
adequate organ functions
Kidney function
adequate organ functions
Liver function
adequate organ functions
Cardiac function
left ventricular ejection fraction (LVEF) >50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA); QTcF interval ≤470 msec
Must have adequate organ functions; left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA); QT interval using Fridericia's formula (QTcF) interval >470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Henry Ford Health System · Detroit, Michigan
- Washington University · St Louis, Missouri
- Mary Crowley Cancer Research · Dallas, Texas
- University of Utah Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify